Kiltearn Partners LLP purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 94,871 shares of the biopharmaceutical company’s stock, valued at approximately $11,986,000. Gilead Sciences accounts for about 2.9% of Kiltearn Partners LLP’s investment portfolio, making the stock its 12th biggest holding.
Several other large investors have also modified their holdings of GILD. BlackRock Inc. bought a new position in Gilead Sciences in the 2nd quarter worth $15,393,785,000. Norges Bank acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $2,617,152,000. Deutsche Bank AG bought a new position in shares of Gilead Sciences in the second quarter worth about $918,387,000. Boston Partners acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $517,808,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Gilead Sciences during the 2nd quarter valued at approximately $398,905,000. 83.67% of the stock is owned by institutional investors.
Gilead Sciences Stock Up 1.9%
GILD opened at $146.12 on Friday. The company has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm’s fifty day moving average price is $131.97 and its two-hundred day moving average price is $136.59. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.
Gilead Sciences Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio is presently -122.85%.
Insider Buying and Selling
In related news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares in the company, valued at $22,918,780.56. This trade represents a 1.78% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $130.31, for a total value of $1,954,650.00. Following the completion of the sale, the chief executive officer directly owned 592,133 shares in the company, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 87,000 shares of company stock worth $11,562,960 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have commented on GILD. Truist Financial dropped their price target on Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Barclays dropped their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Morgan Stanley dropped their price objective on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Cantor Fitzgerald restated an “overweight” rating and set a $155.00 price target on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Weiss Ratings cut Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $158.04.
View Our Latest Stock Report on Gilead Sciences
Gilead Sciences Company Profile
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
- Five stocks we like better than Gilead Sciences
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
